Triple-negative breast cancer

Exam relevance: in 25 of more than 150 board exam reports · rank 30

Specialty
Gynaecology · Breast
Images
Ultrasound 2
Exam relevance
25 of more than 150 reports · rank 30
In the app
1 flashcard · GynFuchs
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Classification
  4. Occurrence & epidemiology
  5. Aetiopathogenesis
  6. Clinical features
  7. Histology
  8. Diagnosis
  9. Treatment principles
  10. Keep learning in the app
  11. Further reading (selection)
  12. Cross-references

Images (2)

Triple-negative breast cancer – Breast ultrasound: hypoechoic, ill-defined lesion with posterior acoustic shadowingUltrasound
Breast ultrasound: hypoechoic, ill-defined lesion with posterior acoustic shadowingImage: SCiardullo, “Caso 1 Ecografia 1” (Wikimedia Commons) · CC BY-SA 3.0 · Source · cropped
Triple-negative breast cancer – ultrasound image: Axillary lymph nodes in breast cancer: rounded, hypoechoic, with loss of the fatty hilum (elastogram on the right)Ultrasound
Axillary lymph nodes in breast cancer: rounded, hypoechoic, with loss of the fatty hilum (elastogram on the right)Image: Jenssen C. et al. (Cancers 2026) · CC BY 4.0 · Source · cropped
1 / 2

Definition

Why it is unfavourable

  • Definition: Triple-negative means: oestrogen receptor, progesterone receptor and HER2 are negative.
  • Typical features: Characteristic features are young age at diagnosis, high grade, high Ki-67 and early visceral metastases.
  • Breast cancer lacking oestrogen and progesterone receptors and making little or no HER2, i.e. negative for all three biomarkers.

Classification

  • BRCA1-associated breast cancers fall mostly within the triple-negative group and overlap with the basal-like subtype.

Occurrence & epidemiology

Epidemiology

  • About 15% of all breast cancers are triple-negative.
  • Triple-negative breast cancer is often diagnosed at a younger age and is more common, and diagnosed earlier, in Black women.
  • Women with changes in BRCA1 or BRCA2 are more frequently affected.

Aetiopathogenesis

Aetiology and pathogenesis

  • The cause is unknown, and the other risk factors are the same as for other breast cancers.
  • In a large series of BRCA2 carriers, 16% had triple-negative tumours.

Clinical features

  • Triple-negative breast cancer is usually diagnosed at a later stage, grows more quickly and is more likely to recur than other invasive breast cancers.
  • Because of its rapid growth it is rarely diagnosed as DCIS (stage 0) and is almost always invasive.
  • Symptoms are the same as for most other breast cancers, but symptoms may also be absent.

Histology

  • BRCA1-associated, mostly triple-negative carcinomas more often show medullary histology and a higher histological grade.

Diagnosis

  • After imaging with mammography, ultrasound or MRI and biopsy, biomarker tests on tumour tissue reveal the triple-negative status.
  • PET or CT serve to assess spread; staging combines the extent of spread, triple-negative status and tumour grade.
  • Among women with triple-negative breast cancer, germline BRCA1 variants are found more often, particularly when diagnosed before the age of 50.

Treatment principles

  • As neither endocrine nor HER2-targeted therapy is effective, chemotherapy is central; for relevant tumour size or nodal involvement it is given neoadjuvantly, combined with an immune checkpoint inhibitor in early high-risk disease.
  • The aim is pathological complete response; if residual tumour remains, post-neoadjuvant therapy follows, with a PARP inhibitor in germline BRCA mutation carriers.
  • Germline testing for BRCA1 and BRCA2 is part of the work-up; in metastatic disease, chemotherapy plus an immune checkpoint inhibitor for PD-L1 positive tumours and antibody-drug conjugates are used.

Specific treatment regimens with drugs and doses are covered in the GynFuchs app.

Keep learning in the app

In the GynFuchs app you can learn Triple-negative breast cancer with flashcards, exam questions and image tasks (colposcopy, ultrasound, CTG) – free, in your browser or as an app.

In the app: 1 flashcard on this topic

Open in browser  About GynFuchs →

Further reading (selection)

  1. National Cancer Institute: What Is Triple-Negative Breast Cancer (TNBC)?
  2. National Cancer Institute: BRCA1 and BRCA2 (PDQ®), health professional version
  3. DocCheck Flexikon, Triple-negatives Mammakarzinom

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the GynFuchs app – free, in your browser or as an app.

Related pages: B3 lesions of the breast · Ductal carcinoma in situ (DCIS) · Fibroadenoma

Note: Learning content from the GynFuchs app (flashcards, exam questions, image cases) for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.